Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.


Anti-cancer treatment designed to lower risk of cancer’s return

New trial evaluating treatment designed to lower the risk of cancer returning Dr. Edward Garon’s Novartis CACZ885T2301 study is now open to enrollment at select TRIO- US sties. This is a randomized phase 3 study evaluating the efficacy an…


Combination Therapy Study Reduces Risk of Death by Half

From Business Wire Combination Therapy Merck announced on August 20, 2018, that the U.S. Food and Drug Administration (FDA) has approved an expanded label for pembrolizumab/KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with peme…


Broad-Based Testing: Will it Improve Survival?

From Cure Magazine: Broad-based genomic sequencing, is useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC). But, it may not improve survival outcomes when compared to routine genomic testing, according t…


FDA Approves Opdivo for Small Cell Lung Cancer

From MedScape The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based c…


Researchers Use Big Data to Predict Immunotherapy Responses

From EurekAlert In the age of Big Data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments. Researchers at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy develo…


Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer

From NewsWise Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden (TMB) accurately identifies non-small cell lung cancer (NSCLC) patients who could benefi…


Lung cancer mortality rates among women projected to increase

From EurekaAlert Bottom Line: The global age-standardized lung cancer mortality rate among women is projected to increase by 43 percent from 2015 to 2030, according to an analysis of data from 52 countries. The global age-standardized breast…


Could a Simple Blood Test Detect Early-Stage Lung Cancer?

from The ASCO Post If the initial promise of research presented at the 2018 ASCO Annual Meeting bears fruit, we may one day have a simple blood test to screen for early-stage lung cancer and possibly other cancers. Although it is still ver…


Blood test improves lung cancer risk assessment for smokers

  From Medical Life Sciences News A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smoke…


Combination Therapy New Standard of Care for Squamous NSCLC

From ASCO Daily News Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival in patients with metastatic squamous non–small cell lung cancer (NSCLC), according to data f…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson